Wire · founder news, decoded · opportunities

Pharmacy Benefit Manager Reaches Settlement with FTC Requiring Changes to Drug ...

20 July 2026 · By Derek Watson · Wire by Fusion42

◆ Published

20 July 2026

◆ Topic

opportunities

◆ Sectors

Digital Health

◆ Geography

United States

◆ Source

Read at duanemorris.com →

◆ Verified

Fusion42 · 20 July 2026 · Fusion42 review

The FTC settled its antitrust case against Caremark (one of three largest PBMs controlling 80% of US prescriptions), requiring structural changes to drug pricing, rebate pass-through to patients, insulin cost caps, and prohibition of hub pharmacies. The settlement estimates $8.5bn in consumer savings over 10 years, with Express Scripts having settled in February 2026 and Optum's case pending.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.

◆ The Wire takeaway

If you supply drugs, pharmacies, or patient assistance services, the rules around PBM rebates and formulary access just changed—and the three largest PBMs have now accepted structural changes that will reshape how they negotiate with you. Rebates that were quietly retained are now flowing to patients; the middleman's ability to lock you out of formularies based on pricing just got constrained.

◆ Related on Wire

◆ Topics

Digital Health · pbm-regulation · drug-pricing · antitrust-enforcement · pharmacy-distribution · vertical-integration